Departments of Neurology and Population Health, New York University Langone Health (Minen); City College of New York (Gopal); Barnard College, New York (Sahyoun); and Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston (Torous).
J Neuropsychiatry Clin Neurosci. 2021 Winter;33(1):72-79. doi: 10.1176/appi.neuropsych.19120353. Epub 2020 Jul 16.
There are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies.
This was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer's disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were <$5.00 to purchase, solely motor versus cognitive-based intervention, or designed for use by caregivers or health care providers. Data abstracted included function, behavior change rewards, and information about intervention, privacy policy, and payment.
Eighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer's disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). Sixty-nine percent of apps had an intervention component, 18% were deemed evidence based, 77% had a privacy policy, 70% required payment for access to all features, and 19% rewarded user behavior changes.
Most apps on the market targeted migraine, depression, and anxiety and contained interventions, although most of the interventions did not appear to be evidence based. Additionally, although most apps had privacy policies, lay people may have difficulty understanding these policies due to their complexities.
市场上有超过 325000 个与健康相关的智能手机应用程序(apps)。为了更好地了解目前针对五种最致残神经精神疾病的市场应用程序,作者进行了一项研究,调查了它们的预期用途(目标人群和干预措施)、收集的数据以及任何隐私政策。
这是一项针对世界卫生组织(WHO)列出的五种最致残神经精神疾病的应用程序的横断面研究:中风、偏头痛、抑郁、阿尔茨海默病和痴呆以及焦虑。根据以下预先规定的纳入标准,在美国的 Google Play 和苹果应用商店中选择了多达 15 个应用程序:该应用程序出现在前 50 个搜索结果中,提供干预或跟踪功能,并在应用程序标题或描述中列出了该疾病。排除标准为购买价格低于 5.00 美元、仅针对运动而不是认知干预、或专为护理人员或医疗保健提供者设计的应用程序。提取的数据包括功能、行为改变奖励以及有关干预措施、隐私政策和付款的信息。
共审查了 83 个应用程序(中风,N=8;偏头痛,N=25;阿尔茨海默病和痴呆,N=8;抑郁,N=7;焦虑,N=14;同时针对抑郁和焦虑的应用程序,N=21)。69%的应用程序具有干预组件,18%被认为是基于证据的,77%有隐私政策,70%需要支付访问所有功能的费用,19%奖励用户行为改变。
市场上大多数应用程序针对偏头痛、抑郁和焦虑,并包含干预措施,尽管大多数干预措施似乎没有基于证据。此外,尽管大多数应用程序都有隐私政策,但由于其复杂性,普通民众可能难以理解这些政策。